API
< Back to all clusters
[HEALTH] · Italy, United States · 13 sources

started · updated

GLP-1 therapy discontinuation linked to doubled cardiovascular risk

A study published in The Lancet Regional Health Europe indicates that stopping GLP-1 receptor agonist therapy is associated with a doubled risk of non-fatal heart attack, non-fatal stroke, or death compared to those who continue treatment. The research, which analyzed electronic health records from over 80,000 patients across more than 300 diabetes centers in Italy, found that approximately four major cardiovascular events occurred per 100 people annually among those who stopped the medication, compared to two per 100 among those who continued.

The increased risk was particularly pronounced in individuals with obesity (a BMI above 30), who experienced a 127 percent higher cardiovascular risk after discontinuing treatment, whereas those without obesity saw a 61 percent increase. Researchers noted that the heightened risk persisted even when weight, blood sugar, and blood pressure remained largely unchanged after stopping the medication, suggesting these factors may not fully explain the increased danger.

While the observational study cannot definitively prove that discontinuing GLP-1s directly causes the increased risk, it highlights significant health implications for patients who stop treatment due to gastrointestinal side effects, high costs, or perceived lack of efficacy. Another study from UT Southwestern Medical Center reported that GLP-1 users had a 38 percent lower risk of obesity-related cancer compared to insulin users after three years, a difference that grew to 39 percent after five years.

Entities

Antonio Ceriello · FDA · Italy · The Lancet Regional Health Europe · UT Southwestern Medical Center

Claims

What the coverage asserts, and how many sources carry each claim.

Sources